News Search Results
Nov 21, 2024, 03:30 ET Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine & Strengthens Board with Appointments of World Class Veterans
Gyroscope, which was acquired by Novartis in 2021 for up to $1.5bn. Khurem was Senior Vice President of the Immunology and Ophthalmology business unit at Genentech, a member of the Roche Group, where he played a key role in the commercialisation and launch strategies of several medicines
More news about: Vicebio
Nov 21, 2024, 03:14 ET RSNA 2024 spotlight: Sectra showcases how radiologists can gain increased diagnostic throughput without working more hours
#8113, Sectra will showcase its complete enterprise imaging portfolio comprised of diagnostic modules (radiology, cardiology, pathology, orthopaedics, ophthalmology and genomics), with its VNA and 'Best in KLAS PACS' at its core — all delivered as a software-as-a-service. Selected highlights featured
More news about: Sectra
Nov 21, 2024, 03:11 ET RSNA 2024 spotlight: Sectra showcases how radiologists can gain increased diagnostic throughput without working more hours
#8113, Sectra will showcase its complete enterprise imaging portfolio comprised of diagnostic modules (radiology, cardiology, pathology, orthopaedics, ophthalmology and genomics), with its VNA and 'Best in KLAS PACS' at its core — all delivered as a software-as-a-service. Selected highlights featured
More news about: Sectra
Nov 20, 2024, 00:01 ET Dômes Pharma Announces U.S. Renaming of SentrX Animal Care to Dômes Pharma, Inc. and Acquisition of NeoPolyBac Veterinary Label
Utah), which develops and manufactures ophthalmology products, based on an exclusive patented technology that potentiates the action of Hyaluronic acid on the eye of animals. With this acquisition, Dômes Pharma strengthens its world leadership in veterinary ophthalmology while creating a launch pad for its
More news about: Dômes Pharma Group
Nov 18, 2024, 17:40 ET Disposable Medical Supplies Market to Grow by USD 604.17 Billion (2024-2028), Driven by Rising Demand, with AI Redefining Market Landscape - Technavio
cross-contamination and surgical-site infection concerns. Physicians and surgeons in various specialties, including Cardiovascular, Cerebrovascular, Ophthalmology, Gynecology, Urology, and Orthopedics, rely heavily on disposable medical supplies such as gloves, bandages, drapes, syringes, suction catheters,
More news about: Technavio
Nov 18, 2024, 11:00 ET Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics
More news about: Mallinckrodt plc
Nov 18, 2024, 09:00 ET C Ray Therapeutics Completes Over $100 Million Series A+ Financing, Jointly Led by SCGC and TaiLong Capital
medicines. The company holds over 100 national invention patents and offers more than 40 products, covering nephrology, oncology, autoimmune diseases, ophthalmology, and dermatology. 3SBio operates four R&D centers, including the National Engineering Research Center for Antibody Drugs and dual platforms
More news about: C Ray Therapeutics
Nov 18, 2024, 07:00 ET Emmecell Announces Positive Topline Results from Randomized, Double-masked Trial of Groundbreaking Non-surgical Cell Therapy for Corneal Edema
proof-of-concept trial," said Jeffrey L. Goldberg, MD, PhD, co-founder of Emmecell and professor and chair of ophthalmology at Stanford University. "These findings strongly support advancing EO2002 into Phase 3 trials, bringing us closer to
More news about: Emmecell
Nov 15, 2024, 10:01 ET Gene Editing Market to Hit USD 7.59 Billion by 2029 with 10.2% CAGR | MarketsandMarkets™
application in 2023. The drug discovery & development segment is further sub segmented into blood disorders, cancer, CNS and others which include Ophthalmology, infections and dystrophies among others. The rising trend of companies exploring and developing gene therapies for these disorders is driving the
More news about: MarketsandMarkets
Nov 14, 2024, 17:31 ET Presbyopia Treatment Market Set to Reach New Heights with New Therapies and Advancements by 2034 | DelveInsight
enhance near vision while maintaining distance vision. Two FDA-approved treatments, VUITY and QLOSI, represent significant advancements in ophthalmology. Learn more about the FDA-approved presbyopia drugs @
More news about: DelveInsight Business Research, LLP
Nov 14, 2024, 14:05 ET Photodynamic Therapy Market to Grow by USD 2.35 Billion (2024-2028), Driven by Rising Cancer Prevalence, AI-Powered Report Highlights Market Trends - Technavio
photosensitizer drug and light energy to destroy cancer cells and other targeted tissues. PDT is commonly used in the fields of oncology, dermatology, and ophthalmology. The market is driven by the increasing prevalence of diseases treatable by PDT, technological advancements, and growing awareness and acceptance
More news about: Technavio
Nov 14, 2024, 09:05 ET Mallinckrodt to Present at Jefferies London Healthcare Conference
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics
More news about: Mallinckrodt plc
Nov 14, 2024, 09:00 ET Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Approved for 2 Clinical Trials by CDE of NMPA
R&D engine, including 11 novel drug candidates and 4 biosimilars. We focus on the therapeutic areas of oncology, immunology, bone disorders, ophthalmology, hematology and infectious diseases, etc. Of these, 3 products have been approved and commercialized, 1 product has been filed for MA, 3 products
More news about: Mabwell
Nov 14, 2024, 03:00 ET Mallinckrodt announces the 2024 Winner of the Extracorporeal Immunomodulation Award
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics
More news about: Mallinckrodt plc
Nov 13, 2024, 14:15 ET Cell and Gene Therapy Market to Grow by USD 6.56 Billion (2024-2028), Driven by Rising Prevalence of Chronic Diseases, AI-Powered Report Explores Market Evolution - Technavio
Mitochondrial genetics, Clinical study protocols, and Infectious disease treatments are also part of this dynamic sector. Oncology, Hematology, Ophthalmology, and Neurological disorders are major indications. Gene therapy, Cell therapy, Gene editing, Tissue regeneration, Invivo gene transfer, and Tcell
More news about: Technavio
Nov 13, 2024, 08:00 ET Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner
management support across a broad spectrum of therapeutic areas, including orphan diseases, oncology, immunology, cardio-renal disorders, neurology, and ophthalmology. Read Travis' full bio
More news about: Flagship Pioneering
Nov 12, 2024, 07:45 ET Capsida Biotherapeutics to Present New Preclinical Data for Potential Best-in-Class Friedreich's Ataxia Next-Generation Gene Therapy
Royal Hotel London Tower Bridge, Minories SuitePresenter: Celeste Stephany, Ph.D., Director of CNS and Ophthalmology Preclinical Research, Capsida About Capsida BiotherapeuticsCapsida Biotherapeutics is a fully integrated gene therapy company
More news about: Capsida Biotherapeutics
Nov 11, 2024, 15:30 ET Avirmax Inc. to Present at the ARVO Frontiers in Ocular Gene Therapy Research Conference
13th, 12:00 – 1:15 pm ET. The Association for Research in Vision and Ophthalmology (ARVO), is the largest international society dedicated to ophthalmology and vision (
More news about: Avirmax
Nov 08, 2024, 10:00 ET Anesthesia Monitoring Devices Market is expected to generate a revenue of USD 32.05 Billion by 2031, Globally, at 7.60% CAGR: Verified Market Research®
Global Anesthesia Drugs Market Size By Application (General Surgery, Orthopedic Surgery, Ophthalmology, Dentistry, Pain Treatment), By Administrative Route (Inhalational, Intravenous (IV), Topical, and Local Infiltration), By Mode of Delivery (Pre-filled
More news about: Verified Market Research
Nov 08, 2024, 09:00 ET Mabwell Reveals Encouraging Pre-clinical Data of 7MW4811 at the 15th World ADC Conference
11 novel drug candidates and 4 biosimilars. We focus on the therapeutic areas of oncology, immunology, bone disorders, ophthalmology, hematology and infectious diseases, etc. Of these, 3 products have been approved and commercialized, 1 product has been filed for MA, 3
More news about: Mabwell
Nov 07, 2024, 13:55 ET Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market Evolution - Technavio
1.1 In vivo1.2 Ex vivoTherapy Area2.1 Oncology2.2 CNS2.3 Ophthalmology2.4 Rare diseases2.5 OthersGeography 3.1 North America3.2
More news about: Technavio
Nov 07, 2024, 07:00 ET Renowned Retinal Surgeon and Medical Entrepreneur, Sunil Gupta, MD, Joins Nanoscope Board of Directors
Gupta earned his medical degree from the University of Cincinnati College of Medicine and completed his residency in Ophthalmology at the Cullen Eye Institute at Baylor College of Medicine in Houston, Texas. He completed
More news about: Nanoscope Therapeutics
Nov 06, 2024, 16:05 ET REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates
a treatment to address both the neurocognitive and systemic effects of MPS II. The recent fellow eye data presented at the American Academy of Ophthalmology meeting demonstrate the potential of ABBV-RGX-314 to preserve vision long-term for patients with wet AMD as a one-time treatment for both eyes.
More news about: REGENXBIO Inc.
Nov 06, 2024, 08:30 ET InMode to Present at Upcoming Investor Conferences
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
More news about: InMode Ltd.
Nov 05, 2024, 06:45 ET Mallinckrodt plc Reports Third Quarter 2024 Financial Results and Raises Full Year Guidance
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics
More news about: Mallinckrodt plc